Paolo Tarantino: An interesting biomarker study of DB04. Two notable findings at ESMO24

Paolo Tarantino shared a post on X:

“Among the many great ESMO24 posters there was an interesting biomarker study of DB04.

2 notable findings:

-HER2 mRNA seems to predict T.

-DXd PFS better than IHC.

Confirms that we need quantitative assays. -T-DXd had shorter PFS in pts with BRCA mutations. Surprising. Prior PARPi?”

Source: Paolo Tarantino/X

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a  publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.